Headquartered in Philadelphia, PA Fiscal year ends December NASDAQ: IPSC centurytx.com
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-transition-stage biotechnology company developing off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune disease, including type 1 diabetes, and other severe diseases. Its therapies come from an in-house iPSC cell foundry and use its proprietary Allo-Evasion immune-evasion engineering technology, which is designed to let donor-derived cells avoid rejection without patient-specific manufacturing.
The company has two lead programs:
- **CNTY-813:** an Allo-Evasion 5.0-edited, iPSC-derived islet replacement therapy for type 1 diabetes, with an IND submission planned for 4Q 2026.
- **CNTY-308:** a CD19-targeted CAR-iT cell therapy for autoimmune disease, expected to enter the clinic in 2026.
Century currently generates no product revenue. It has historically recognized collaboration revenue and funds operations from cash and investments that it expects to last into 1Q 2029. Updated
A $174.1 million cash position now funds Century into the first quarter of 2029, more than half the company's entire market cap. The loss met expectations and narrowed as R&D spending came down, with an IND filing for diabetes candidate CNTY-813 due this quarter.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-transition-stage biotechnology company developing off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune disease, including type 1 diabetes, and other severe diseases.
The Wall Street consensus 12-month price target for IPSC is $4.75.